• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • OncoFAP-Radio Conjugate
    • OncoFAP-Drug Conjugate
    • Onco IX (PHC-102, Imaging)
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • OncoFAP-Radio Conjugate
    • OncoFAP-Drug Conjugate
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering

Philogen Q3 2021 Virtual Briefing

by last | Nov 15, 2021 | 2021, Investors, Past Events

Listen to Webcast

Recent Posts

  • Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)
  • Philogen to attend the Society for Immunotherapy of Cancer’s 37th Annual Meeting 2022 in Boston (8-12 November 2022)
  • Philochem will be attending the 10th World ADC Conference in London
  • Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging
  • Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch